Actuate Therapeutics, Inc., a Chicago, IL- and Forth Worth, TX-based clinical stage biopharmaceutical company, raised an additional $6.5M in a Series B-3 financing round.
This Series B-3, which brought total funding for Actuate’s Series B round to over $28.2M, was led by Bios Partners with participation from Kairos Ventures, DEFTA Partners, and other existing investors.
The company intends to use the funds to initiate a Phase 2 clinical trial in myelofibrosis and expand its ongoing 1801 clinical trial to include an arm for treating patients with a combination of 9-ING-41 with irinotecan.
Led by Daniel Schmitt, President & CEO, and Dr. Frank Giles, Chief Medical Officer, and Dr. Ludimila Cavalcante, Lead, Medical Affairs, Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer or inflammatory diseases.
The 1801 clinical trial was designed as a histology agnostic study with seamless extension from the investigation of single agent therapy to that of six different 9-ING-41-based combinations with standard-of-care chemotherapeutics. The initial combinations were prioritized based on evidence of reversal of resistance to key cytotoxic agents in diverse pre-clinical models.